Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells

Clinical reports indicate that patients with primary aldosteronism commonly have impaired glucose tolerance; however, the relationship between aldosterone and insulin signaling pathway has not been clarified. In this study, we examined the effects of aldosterone treatment on insulin receptor substrate-1 expression and insulin signaling pathway including Akt phosphorylation and glucose uptake in rat vascular smooth muscle cells. Insulin receptor substrate-1 protein expression and Akt phosphorylation were determined by Western blot analysis with anti-insulin receptor substrate-1 and phosphorylated-Akt antibodies, respectively. Glucose metabolism was evaluated using 3H-labeled 2-deoxy-d-glucose uptake. Aldosterone (1–100 nmol/L) dose-dependently decreased insulin receptor substrate-1 protein expression with a peak at 18 hours (n=4). Aldosterone-induced degradation of insulin receptor substrate-1 was markedly attenuated by treatment with the selective mineralocorticoid receptor antagonist eplerenone (10 &mgr;mol/L; n=4). Furthermore, degradation was blocked by the Src inhibitor PP1 (20 &mgr;mol/L; n=4). Treatment with antioxidants, N-acetylcysteine (10 mmol/L), or ebselen (40 &mgr;mol/L) also attenuated aldosterone-induced insulin receptor substrate-1 degradation (n=4). In addition, proteasome inhibitor MG132 (1 &mgr;mol/L) prevented insulin receptor substrate-1 degradation (n=4). Aldosterone treatment abolished insulin-induced Akt phosphorylation (100 nmol/L; 5 minutes; n=4). Furthermore, aldosterone pretreatment decreased insulin-stimulated (100 nmol/L; 60 minutes; n=4) glucose uptake by 50%, which was reversed by eplerenone (10 &mgr;mol/L; n=4). These data indicate that aldosterone decreases insulin receptor substrate-1 expression via Src and reactive oxygen species stimulation by proteasome-dependent degradation in vascular smooth muscle cells; thus, aldosterone may be involved in the pathogenesis of vascular insulin resistance via oxidative stress.

[1]  T. Kurtz,et al.  Molecular genetics of experimental hypertension and the metabolic syndrome: from gene pathways to new therapies. , 2007, Hypertension.

[2]  M. Reincke,et al.  Primary aldosteronism: current knowledge and controversies in Conn's syndrome , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[3]  B. Rodrigues,et al.  Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. , 2007, American journal of physiology. Endocrinology and metabolism.

[4]  F. Turchi,et al.  Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study , 2007, Journal of hypertension.

[5]  J. Sowers,et al.  Angiotensin II-induced NADPH Oxidase Activation Impairs Insulin Signaling in Skeletal Muscle Cells* , 2006, Journal of Biological Chemistry.

[6]  D. DeFranco,et al.  Mechanisms of Disease: regulation of glucocorticoid and receptor levels—impact on the metabolic syndrome , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[7]  L. Sechi,et al.  Insulin sensitivity in patients with primary aldosteronism: a follow-up study. , 2006, The Journal of clinical endocrinology and metabolism.

[8]  K. Griendling,et al.  Reactive oxygen species signaling in vascular smooth muscle cells. , 2006, Cardiovascular research.

[9]  A. Nishiyama,et al.  Synergistic effect of mechanical stretch and angiotensin II on superoxide production via NADPH oxidase in vascular smooth muscle cells , 2006, Journal of hypertension.

[10]  E. Ferrannini,et al.  The Metabolic Syndrome: Time for a Critical Appraisal , 2006 .

[11]  N. Kobayashi,et al.  Cardioprotective Mechanisms of Eplerenone on Cardiac Performance and Remodeling in Failing Rat Hearts , 2006, Hypertension.

[12]  A. Nishiyama,et al.  Aldosterone Stimulates Vascular Smooth Muscle Cell Proliferation Via Big Mitogen-Activated Protein Kinase 1 Activation , 2005, Hypertension.

[13]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[14]  Y. Fujita,et al.  ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. , 2005, Experimental cell research.

[15]  J. Klein,et al.  Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[16]  R. Alexander,et al.  Mechanisms of Reactive Oxygen Species–Dependent Downregulation of Insulin Receptor Substrate-1 by Angiotensin II , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[17]  K. Petersen,et al.  Mechanisms of insulin resistance in humans and possible links with inflammation. , 2005, Hypertension.

[18]  E. Schiffrin,et al.  Aldosterone Activates Vascular p38MAP Kinase and NADPH Oxidase Via c-Src , 2005, Hypertension.

[19]  R. Carey,et al.  The renin–angiotensin–aldosterone system, glucose metabolism and diabetes , 2005, Trends in Endocrinology & Metabolism.

[20]  P. Seshiah,et al.  Phosphoinositide-Dependent Kinase 1 and p21-Activated Protein Kinase Mediate Reactive Oxygen Species–Dependent Regulation of Platelet-Derived Growth Factor–Induced Smooth Muscle Cell Migration , 2004, Circulation research.

[21]  Y. Kaburagi,et al.  Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. , 2004, Endocrine journal.

[22]  M. Tuck,et al.  The effect of aldosterone on glucose metabolism , 2003, Current hypertension reports.

[23]  M. White,et al.  IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.

[24]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[25]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[26]  E. Frohlich,et al.  Diabetes, Hypertension, and Cardiovascular Disease: An Update , 2001, Hypertension.

[27]  R. Loftus,et al.  The alpha-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5'-flanking region of the gene. , 2001, Molecular endocrinology.

[28]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[29]  Y. Miyazaki,et al.  Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? , 1994, Journal of human hypertension.

[30]  J. Sowers,et al.  Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. , 1993, American journal of hypertension.

[31]  J. Conn.  Hypertension, the potassium ion and impaired carbohydrate tolerance. , 1965, The New England journal of medicine.

[32]  L. Jian.  Oxidative Stress and Diabetic Cardiovascular Complications , 2007 .

[33]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[34]  J. Widimský,et al.  Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. , 2004, The Journal of clinical endocrinology and metabolism.

[35]  B. Pitt,et al.  Eplerenone , a Selective Aldosterone Blocker , in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[36]  T. Zelinka,et al.  Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity , 2002, Journal of Human Hypertension.